ImmunoGen Announces Investigational New Drug Application for IMGN632 for Hematological Malignancies is Active
ImmunoGen,Inc. | October 16, 2017
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has completed the safety review of its investigational new drug (IND) application for IMGN632 in patients with CD123-positive hematological malignancies.